Grit Biotechnology
Clinical trials sponsored by Grit Biotechnology, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immune cells from your own tumor could fight cervical cancer Results expected Jan 2027 (estimated)
- Immune cells from your tumor could fight cancer again Results expected Apr 2027 (estimated)
- Patient's own immune cells take on head and neck cancer in new trial Results expected Apr 2027 (estimated)
- Immune cells harvested from tumors could fight advanced colorectal cancer Results expected May 2027 (estimated)
- Immune cells from your own tumor could fight cancer Results expected Jun 2027 (estimated)
-
Experimental cell therapy targets kidney disease
Disease control Not yet recruitingThis early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Off-the-Shelf immune cells take aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThis early-phase trial is testing an experimental therapy called GT737 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. GT737 uses specially engineered immune cells (iNKT cells) that are made in large batches and can be given…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC